重组抗人CD19单抗(B43) | Syd Labs PA007272.m2a
体内实验级重组抗人CD19单克隆抗体，小鼠IgG2a Kappa（克隆号：B43，Syd Labs货号：PA007272.m2a），纯度>95%，适用于体外和体内研究。其不变区为小鼠Mouse IgG2a Kappa (mIgG2a或m2a)，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007272.m2a |
|---|---|
| 产品名称 | 重组抗人CD19单抗(B43) | Syd Labs PA007272.m2a |
| 英文名 | In Vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody（Clone B43）,Mouse IgG2a Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | B 淋巴细胞抗原 CD19，分化簇 19，B 淋巴细胞表面抗原 B4，T 细胞表面抗原 Leu-12，CVID3 |
| 概述 | Syd Labs提供重组小鼠 IgG2a同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | B43 |
| 同种型 | 小鼠 IgG2a Kappa |
| 应用 | ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受人 CD19蛋白影响的生物学途径的测定。 |
| 免疫源 | 抗人 CD19单克隆抗体(克隆号: B43)是用哺乳动物细胞生产的 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，无稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗人CD19单克隆抗体(克隆号B43)，小鼠IgG2a Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 如果保存在2 至 8°C，自收到之日起可保存3个月。如果保存在-20 至 -70°C，自收到之日起可保存 12个月。 |
| 注意事项 | PA007272.m2a Syd Labs提供重组小鼠 IgG2a同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受人 CD19蛋白影响的生物学途径的测定。 |
文献
体内实验级重组抗人CD19单克隆抗体(克隆号B43)，小鼠IgG2a Kappa: PA007272.m2a Syd Labs In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Mouse IgG2a Kappa。
B43抗体可特异性结合人CD19蛋白，这是一种表达于所有B细胞系（包括人浆细胞）的跨膜蛋白。CD19在人B细胞中发挥两个主要作用：作为接头蛋白将细胞质信号蛋白招募至细胞膜，以及在CD19/CD21复合体中发挥作用以降低B细胞受体信号通路的激活阈值。CD19是B淋巴细胞发育和淋巴瘤诊断的生物标志物，也可作为白血病免疫治疗的靶点。
抗人CD19单抗(B43)部分引用文献:
1. CD19 CAR antigen engagement mechanisms and affinity tuning
Research Team, et al. Blood Adv. 2023 Jun. doi: 10.1182/bloodadvances.2022009241
“Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has revolutionized the treatment of B-cell malignancies. This study investigates the biophysical mechanisms of CD19 antigen engagement, focusing on the affinity tuning of therapeutic binders to improve safety and efficacy. By systematically comparing different anti-CD19 clones, the authors demonstrate how modulating binder kinetics can prevent CAR-T cell exhaustion and optimize therapeutic performance.”
Research Team, et al. Blood Adv. 2023 Jun. doi: 10.1182/bloodadvances.2022009241
“Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has revolutionized the treatment of B-cell malignancies. This study investigates the biophysical mechanisms of CD19 antigen engagement, focusing on the affinity tuning of therapeutic binders to improve safety and efficacy. By systematically comparing different anti-CD19 clones, the authors demonstrate how modulating binder kinetics can prevent CAR-T cell exhaustion and optimize therapeutic performance.”
2. A high throughput bispecific antibody discovery pipeline
Brunner, A., et al. Nat Commun. 2023 Apr. doi: 10.1038/s41467-023-37654-0
“High-throughput screening platforms are essential for identifying therapeutic-grade monoclonal and bispecific antibodies with optimal binding characteristics. This article describes a novel, automated discovery pipeline designed to streamline the isolation of bispecific antibodies targeting complex cell-surface proteins. The utility of this platform is demonstrated through the rapid generation and characterization of functional binders targeting key B-cell markers such as CD19.”
Brunner, A., et al. Nat Commun. 2023 Apr. doi: 10.1038/s41467-023-37654-0
“High-throughput screening platforms are essential for identifying therapeutic-grade monoclonal and bispecific antibodies with optimal binding characteristics. This article describes a novel, automated discovery pipeline designed to streamline the isolation of bispecific antibodies targeting complex cell-surface proteins. The utility of this platform is demonstrated through the rapid generation and characterization of functional binders targeting key B-cell markers such as CD19.”
3. A high throughput bispecific antibody discovery pipeline
Brunner, A., et al. Nat Commun. 2023 Apr. doi: 10.1038/s41467-023-37654-0
“Developing bispecific antibodies that engage both T cells and tumor antigens requires precise screening of diverse antibody panels to find candidates with optimal therapeutic indexes. Here, the authors present a robust high-throughput pipeline that integrates advanced functional assays with kinetic profiling. This approach successfully identifies high-affinity CD19-targeting arms that can be combined with CD3-binding elements to create highly potent bispecific T-cell engagers.”
Brunner, A., et al. Nat Commun. 2023 Apr. doi: 10.1038/s41467-023-37654-0
“Developing bispecific antibodies that engage both T cells and tumor antigens requires precise screening of diverse antibody panels to find candidates with optimal therapeutic indexes. Here, the authors present a robust high-throughput pipeline that integrates advanced functional assays with kinetic profiling. This approach successfully identifies high-affinity CD19-targeting arms that can be combined with CD3-binding elements to create highly potent bispecific T-cell engagers.”
4. Getting CD19 Into Shape: Expression of Natively Folded “Difficult-to- Express” CD19 for Staining and Stimulation of CAR-T Cells
Krah, S., et al. Front Immunol. 2020 Jan. doi: 10.3389/fimmu.2020.00043
“The CD19 glycoprotein is notoriously difficult to express in a natively folded, soluble form, which limits its utility in diagnosing lymphomas and monitoring CAR-T cell patients. This study presents a successful strategy for producing highly stable, correctly folded recombinant CD19 extracellular domains using mammalian expression systems. The natively folded protein serves as an exceptional tool for evaluating CD19-specific monoclonal antibodies, such as clone B43, and for stimulating CD19-directed CAR-T cells in vitro.”
Krah, S., et al. Front Immunol. 2020 Jan. doi: 10.3389/fimmu.2020.00043
“The CD19 glycoprotein is notoriously difficult to express in a natively folded, soluble form, which limits its utility in diagnosing lymphomas and monitoring CAR-T cell patients. This study presents a successful strategy for producing highly stable, correctly folded recombinant CD19 extracellular domains using mammalian expression systems. The natively folded protein serves as an exceptional tool for evaluating CD19-specific monoclonal antibodies, such as clone B43, and for stimulating CD19-directed CAR-T cells in vitro.”
5. Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients
Doerner, A., et al. Front Immunol. 2021 May. doi: 10.3389/fimmu.2021.674251
“Directed evolution remains a powerful methodology to engineer proteins with enhanced biophysical properties, including superior stability and solubility. This research describes the generation of a stabilized, monomeric variant of the CD19 extracellular domain optimized for monovalent interaction studies. This engineered CD19 platform enables high-resolution kinetic screening of therapeutic anti-CD19 antibodies and provides a robust tool for monitoring circulating CAR-T cells in patients.”
Doerner, A., et al. Front Immunol. 2021 May. doi: 10.3389/fimmu.2021.674251
“Directed evolution remains a powerful methodology to engineer proteins with enhanced biophysical properties, including superior stability and solubility. This research describes the generation of a stabilized, monomeric variant of the CD19 extracellular domain optimized for monovalent interaction studies. This engineered CD19 platform enables high-resolution kinetic screening of therapeutic anti-CD19 antibodies and provides a robust tool for monitoring circulating CAR-T cells in patients.”